The biopharmaceutical company, the developer of a treatment for atrial fibrillation, raised the cash from investors including industrial corporate SMS.
Germany-based biopharmaceutical company Omeicos Therapeutics raised €6.2m ($6.6m) in a series A round featuring SMS Group, a metallurgical plant operator and mechanical engineering firm, on Wednesday.
The round was led by mid-stage investment fund Vesalius Biocapital Partners with the participation of venture capital fund VC Fonds Technology Berlin, public-private venture capital investment firm High-Tech Gruenderfonds (HTGF), and German state-owned development bank KfW Group.
Omeicos is developing a novel molecule for the treatment and prevention of heart disorder atrial fibrillation.
HTGF…
